Figure 1

Change in immunohistochemistry scores for fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and phosphatase and tensin homolog (PTEN) with decitabine for tumors with scores that were initially low (≤150). By Wilcoxon matched pairs signed rank tests, there was a significant increase in FHIT scores with decitabine (post- versus pre-decitabine median scores 175 versus 100, P = 0.0140), with a strong trend towards an increase in WWOX (post- versus pre-decitabine median scores 100 versus 30, P = 0.0547) and FUS1 (post- versus pre-decitabine median scores 100 versus 67.5, P = 0.0726), but with no major change in PTEN (post- versus pre-decitabine scores 0 versus 0, P = 0.2034). Medians are indicated by horizontal lines on the graphs.